Goodwin Procter advised the Special Committee of Zuora and Freshfields US advised Zuora, Simpson Thacher & Bartlett advised Silver Lake, Dechert advised GIC, Sullivan & Cromwell...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Thoma Bravo on the deal. Thoma Bravo, a leading software investment firm, announced its definitive agreement to acquire 100% of the shares in...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Limelight Networks on the deal. Paul, Weiss, Rifkind, Wharton & Garrison represented Edgecast, Inc. and funds managed by affiliates of Apollo in the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
